Entera Bio Insiders Bet Big on Oral Peptide Platform's Future

TEL AVIV, Israel – February 11, 2026 – Leadership at Entera Bio (NASDAQ: ENTX) is sending a powerful message of confidence to Wall Street, not just with words, but with their own wallets. In a significant series of open market transactions, multiple members of the company's Board of Directors, including its newly appointed Chairman, have purchased thousands of company shares. This wave of insider buying follows a similar purchase by CEO Miranda Toledano late last year, creating a clear pattern of bullish sentiment from those with the deepest insight into the company's future.

The market has taken notice. Following the announcement, Entera's stock surged 13% on February 11th, closing near $1.59. The timing of the directors' purchases, executed on February 9th and 10th at prices ranging from $1.20 to $1.49 per share, suggests a belief that the company's stock was undervalued just ahead of this public display of confidence.

A Sustained Vote of Confidence

This cluster of insider activity is more than a one-off event; it represents a sustained trend. Regulatory filings reveal a series of coordinated acquisitions. On February 10th, Director Haya Taitel purchased 7,500 shares, while Chairman Geno J. Germano, a former Pfizer executive appointed just a day earlier, acquired a substantial 20,000 shares. The day prior, on February 9th, Director Steven D. Rubin bought 10,000 shares, and Director Sean Ellis purchased another 18,000.

These transactions build upon the purchase made by CEO Miranda Toledano in December 2025 and contribute to a larger pattern of net positive insider buying. Over the last twelve months, insiders have purchased nearly 420,000 shares, with almost 160,000 of those shares acquired in just the last three months. In a market often driven by speculation, such consistent buying from a company's own leadership is widely interpreted as a strong signal that they believe significant value-creating milestones are on the horizon.

The Science Fueling the Optimism

The board's optimism appears to be rooted in the tangible scientific and clinical progress of Entera Bio's pipeline, which is built on its proprietary N-Tab® technology. This platform is designed to overcome a major hurdle in medicine: the oral delivery of large molecule drugs like peptides and proteins, which are typically degraded by the digestive system and must be injected. If successful, N-Tab® could transform the standard of care for numerous chronic diseases by replacing inconvenient injections with a simple daily tablet.

Entera's most advanced candidate, EB613, is poised to be the first-ever oral, bone-building (anabolic) therapy for post-menopausal women with high-risk osteoporosis. The program achieved a critical milestone in July 2025 when the U.S. Food and Drug Administration (FDA) agreed that Bone Mineral Density (BMD) could serve as the primary endpoint for its pivotal Phase 3 study. This regulatory clarity is expected to streamline the development pathway. Having already met its primary and secondary endpoints in a 161-patient Phase 2 trial, the company plans to submit its final Phase 3 protocol to the FDA in the first quarter of 2026. A successful oral anabolic treatment could revolutionize a market where patient adherence to injectable therapies is notoriously low.

Beyond osteoporosis, the company is advancing a broad pipeline in partnership with OPKO Health. This includes EB612, an oral therapy for hypoparathyroidism, which is being accelerated into clinical trials this year. Another high-profile program is an oral oxyntomodulin for obesity. As a dual GLP-1/glucagon agonist, it enters a blockbuster market currently dominated by injectables and the single oral GLP-1, Rybelsus®. Entera's candidate aims to offer a competitive oral alternative, with an Investigational New Drug (IND) application planned for the first half of 2026.

Furthermore, its oral GLP-2 program for short bowel syndrome has shown remarkable preclinical results, demonstrating a plasma half-life 18 times longer than the only approved injectable therapy, Gattex®. This could dramatically improve quality of life and treatment adherence for patients with this rare malabsorption condition.

Strategic Maneuvers and a Pivotal Year Ahead

The insider purchases align with a series of strategic corporate moves positioning Entera for a pivotal year. The appointment of Geno J. Germano as Chairman brings seasoned leadership from one of the world's largest pharmaceutical companies. His immediate investment in the company underscores his commitment and belief in its strategic direction.

Financially, Entera reported having $16.6 million in cash and equivalents as of September 30, 2025, which it projects will fund operations through the middle of the third quarter of 2026. This runway provides a critical window to achieve several upcoming catalysts, including the initiation of the EB613 Phase 3 trial and the advancement of its partnered programs with OPKO Health.

While the biotech sector is fraught with risk, as evidenced by Entera's mutually terminated collaboration with Amgen in 2023, the company managed to retain all intellectual property from that deal. Now, with a focused strategy, a promising proprietary technology platform, and a leadership team that is personally invested in the outcome, Entera Bio is signaling that it believes its most significant breakthroughs are still to come.